Biognosys Group presents next-generation multiomics portfolio at ASMS 2026
The Biognosys Group, comprising Bruker affiliates Biognosys, biocrates and PreOmics, has presented a series of advances across its integrated proteomics and metabolomics portfolio at the American Society for Mass Spectrometry (ASMS) annual conference in San Diego, California. Announcements span new software releases, targeted assay collaborations, optimised sample preparation workflows and a hybrid metabolomics platform.
Spectronaut 21 and SpectroMine 6
The headline software releases are Spectronaut 21, for data-independent acquisition (DIA) proteomics, and SpectroMine 6, for data-dependent acquisition (DDA) workflows. Both are cloud-enabled and incorporate AI-driven post-translational modification (PTM) prediction, enhanced PTM site localisation and stoichiometry reporting, and open search functionality for detection of rare modifications. Benchmarking across 65 proteomics datasets demonstrated approximately 10% more protein group identifications, while testing across 27 immunopeptidomics datasets showed roughly 11% more peptide identifications. Computational efficiency has also improved, with directDIA data processing running up to 15% faster.
Yansheng Liu, PhD, Associate Professor at Yale University School of Medicine, commented: “Spectronaut is our preferred DIA analysis software due to its high performance and user-friendly interface, which makes analyzing our complex and multiplex DIA datasets both easy and reliable.”
Prof. Dr. Matthias Mann, Director of the Department of Proteomics and Signal Transduction at the Max Planck Institute of Biochemistry, added: “Spectronaut is an excellent addition to our informatics capabilities, especially for its thorough analysis large scale DIA phosphopeptide data and advanced modification localization algorithm.”
Targeted proteomics for clinical research: Angelman syndrome biomarker
Biognosys has announced a collaboration with SISCAPA Assay Technologies (SAT), combining Biognosys’ quantitative proteomics expertise with SISCAPA’s peptide antibody enrichment for absolute protein quantification. The partnership has produced an ultrasensitive assay for quantifying UBE3A protein levels in human cerebrospinal fluid (CSF), intended to support therapeutic monitoring in patients with Angelman syndrome – a rare neurodevelopmental disorder. The work illustrates how targeted proteomics may support precise biomarker measurement in clinical research settings.
Low-input proteomics: iST-S workflow
The iST-S protocol, an extension of the established PreOmics iST workflow, is designed to deliver deep proteome coverage from sample inputs as low as 0.5 µg. Benchmarking across timsTOF HT and Orbitrap Astral platforms demonstrated consistent identification of approximately 7,500 protein groups from 0.5-10 µg inputs derived from HeLa and HEK293 cells. Across cancer cell line models, identification rates reached up to 10,000 protein groups with a coefficient of variation (CV) of approximately 10%, positioning the workflow for high-throughput, standardised low-input proteomics.
P2 single-particle enrichment for serum and plasma
The optimised P2 single-particle enrichment workflow extends protein corona-based enrichment – previously validated in EDTA plasma – to serum and heparin plasma matrices. Compared to the original P2-iST plasma kit, the updated protocol demonstrated up to a four-fold increase in protein group identifications in serum and heparin plasma, with linearity experiments showing correlation coefficients (R²) of up to 0.97-0.98. An independent study published in the Journal of Proteome Research (Völlmy et al., 2026) reported that P2 achieved the highest depth of approximately 4,040 proteins at 50 µL input, with a median CV of 18.4%.
Markku Varjosalo, PhD, Programme Director at the Institute of Biotechnology, University of Helsinki, noted: “When depth matters, P2-iST consistently comes out on top. For us it has been a game changer – it puts robust, deep plasma proteomics into the hands of any lab without expensive proprietary hardware.”
FFPE tissue proteomics and nanoLC performance
An end-to-end FFPE tissue proteomics workflow combining PreOmics BeatBox and iST sample preparation with PepSep Advanced columns, nanoElute 2, timsTOF, and Spectronaut enables identification of approximately 5,000 protein groups from as few as two FFPE curls, without requiring deparaffinisation. Separately, integration of the Bruker proteoElute LC system with PepSep Advanced columns demonstrated stable operation over 12-day continuous acquisitions, with retention time deviations below 1%, carry-over below 1%, and up to approximately 10,600 protein groups identified depending on gradient length.
Hybrid targeted and untargeted metabolomics
Bruker and biocrates are previewing the MxQuant kit workflow on the timsMetabo platform, combining quantitative targeted metabolomics using biocrates kits with untargeted discovery in a single measurement, using parallel accumulation–serial fragmentation (PASEF). The approach is designed to reduce sample consumption and instrument time whilst maintaining quantitative rigour alongside exploratory breadth. Biognosys is additionally offering biocrates targeted metabolomics as a contract research organisation (CRO) service from its Massachusetts laboratory.
Matthew Lewis, PhD, Bruker’s Vice President for Metabolomics and Lipidomics, said: “By combining quantitative metabolomics with discovery on timsMetabo, we are unifying targeted and untargeted workflows in a way that produces data-rich and future-proof digital metabolome archives.”
For more information, visit: www.biognosysgroup.com
Digital issue: Please click here for more information
